Viracta Therapeutics (FRA:RYI) Change In Payables And Accrued Expense : €2.09 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Change In Payables And Accrued Expense?

Viracta Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €-1.31 Mil. It means Viracta Therapeutics's Accounts Payable & Accrued Expense declined by €1.31 Mil from Dec. 2023 to Mar. 2024 .

Viracta Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €2.83 Mil. It means Viracta Therapeutics's Accounts Payable & Accrued Expense increased by €2.83 Mil from Dec. 2022 to Dec. 2023 .

Viracta Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Viracta Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Change In Payables And Accrued Expense Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

2.17

1.62

0.98

2.83

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial												-0.57	1.29	0.32	1.79	-1.31

Viracta Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.09 Mil.

Viracta Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics (FRA:RYI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

VIRX:USA RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.